California-based DiaCarta is set to expand its genomics testing and diagnostics products range after raising $45m in a series B funding round, led by Chinese firm Fortune Fountain Capital. DiaCarta CEO Aiguo Zhang has big plans for the cash injection, including establishing global clinical study programmes for non-invasive early cancer detection and commercially launching its Xenonucleic Acid Molecular Clamp colorectal cancer detection assay. The company raised $8m In a series A round more than three years ago.
California-based DiaCarta is set to expand its genomics testing and diagnostics products range after raising $45m in a series B funding round, led by Chinese firm Fortune Fountain Capital. DiaCarta CEO Aiguo Zhang has big plans for the cash injection, including establishing global clinical study programmes for non-invasive early cancer detection and commercially launching its ColoScape colorectal cancer detection assay. The company raised $8m In a series A round more than three years ago.